The FDA rejected the initial application in February. Valerie Plesch/Bloomberg News The Food and Drug Administration has agreed to reverse its rejection of Regenxbio’s RGNX -1.27%decrease; down pointing triangle experimental gene therapy for a rare and fatal brain disease, the company said, the latest about-face by the agency under new leadership.